Page 46 - Astrazeneca Evusheld News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Determining which patients are infected with the delta vs. omicron variant is complicated.

We warned from Omicron's onset that most monoclonal antibodies would be ineffective, yet lots of MDs have not gotten the memo.

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

GlaxoSmithKline and Vir Biotechnology are rushing to speed up production of their COVID-19 therapy, now that they're the only companies with an antibody that appears to be truly effective against omicron.

Many hospitals and clinics are still infusing the costly treatments—often charging hundreds of dollars a session—that public health officials now say are almost certainly useless.